Our recent studies suggested that enhanced expression of SOCS3 could reduce tumor metastasis, the expression of epithelial-to-mesenchymal transition (EMT) markers and STAT3 activation in the absence of interleukin-6 (IL-6) stimulation in CCA cell lines [22]. The gene discussed is SOCS3; the disease is cholangiocarcinoma.